Response to hepatitis A vaccine in children with inflammatory bowel disease receiving infliximab

Inflammatory Bowel Diseases

Volumn 17, Issue 12, 2011, Pages

  Moses, Jonathan ^a   Alkhouri, Naim ^a   Shannon, Angela ^a   Feldstein, Ariel ^a   Carter Kent, Christine ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A ANTIBODY; HEPATITIS A VACCINE; INFLIXIMAB; METHOTREXATE;

ADOLESCENT; ADULT; CLINICAL ARTICLE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS A; HUMAN; IMMUNOGENICITY; LETTER; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE; VACCINATION;

CROHN DISEASE; FEMALE; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; MALE;

EID: 80855132584     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21892     Document Type: Letter

References (4)

1. Radzikowski A, Banaszkiewicz A, Lazowska-Przeorek I, et al. Immunogenicity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011; 17: 1117-1124.
2. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA. 1994; 271: 1328-1334. (Pubitemid 24132458)
3. Ferreira CT, da Silveira TR, Vieira SM, et al. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. J Pediatr Gastroenterol Nutr. 2003; 37: 258-261. (Pubitemid 39274514)
4. Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol. 1999; 94: 1601-1604. (Pubitemid 29260452)